Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy

被引：2

作者：

Jewell, Kerry ^{[1
,2
]}

Hofman, Michael S. ^{[1
,2
,3
]}

Ong, Jeremy S. L. ^{[2
,4
]}

Levy, Sidney ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Peter MacCallum Canc Ctr, Prostate Theranost & Imaging Ctr Excellence ProsTI, Dept Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia

[3] Univ Melbourne, Melbourne, Australia

[4] Fiona Stanley Hosp, Dept Nucl Med, Murdoch, Australia

来源：

RADIOLOGY | 2024年 / 311卷 / 01期

关键词：

RADIOLIGAND THERAPY; CLINICAL UTILITY; NORMAL PATTERNS; OPEN-LABEL; TRIAL; PET; MULTICENTER; MANAGEMENT; DOSIMETRY; VISION;

D O I：

10.1148/radiol.231703

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

There is increasing demand worldwide to develop diagnostic and therapeutic (theranostic) markers for prostate cancer. One target of interest is prostate-specific membrane antigen (PSMA), a protein which is overexpressed in prostate cancer cells. Over the past decade, a growing body of literature has demonstrated that radiolabeled ligands that target PSMA show favorable clinical response and survival outcomes in patients with advanced prostate cancer. This focused review provides background to the development of PSMA as a target, an overview of key studies informing our current approach to radioligand-based imaging and therapy for prostate cancer, and a model for real-world implementation of PSMA theranostics based on an Australian experience.

引用

页数：10

共 50 条

[1] Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy (aprl,10.1148/radiol.231703, 2024)
Jewell, Kerry
Hofman, Michael S.
Ong, Jeremy S. L.
Levy, Sidney
[J]. RADIOLOGY, 2024, 311 (03)
[2] Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy
Arsenault, Frederic
Beauregard, Jean-Mathieu
Pouliot, Frederic
[J]. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 359 - 365
[3] Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
Plichta, Kristin A.
Graves, Stephen A.
Buatti, John M.
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
[4] Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option
Mayor, Nikhil
Sathianathen, Niranjan J.
Buteau, James
Koschel, Samantha
Juanilla, Marta Anton
Kapoor, Jada
Azad, Arun
Hofman, Michael S.
Murphy, Declan G.
[J]. BJU INTERNATIONAL, 2020, 126 (05) : 525 - 535
[5] Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer
Mangadlao, Joey Dacula
Wang, Xinning
McCleese, Christopher
Escamilla, Maria
Ramamurthy, Gopalakrishnan
Wang, Ziying
Govande, Mukul
Basilion, James P.
Burda, Clemens
[J]. ACS NANO, 2018, 12 (04) : 3714 - 3725
[6] Biomarkers in Prostate-Specific Membrane Antigen Theranostics
Vlachostergios, Panagiotis J.
Zachos, Ioannis
Tzortzis, Vassilios
[J]. DIAGNOSTICS, 2021, 11 (06)
[7] Prostate-specific membrane antigen radioligand therapy of prostate cancer
Beheshti, Mohsen
Heinzel, Alexander
von Mallek, Dirk
Filss, Christian
Mottaghy, Felix M.
[J]. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01): : 29 - 36
[8] Targeting the prostate-specific membrane antigen for prostate cancer therapy
Buehler, Patrick
Wolf, Philipp
Elsaesser-Beile, Ursula
[J]. IMMUNOTHERAPY, 2009, 1 (03) : 471 - 481
[9] Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer
Emmett, Louise
[J]. SEMINARS IN ONCOLOGY NURSING, 2020, 36 (04)
[10] Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics
Murphy, Declan G.
Azad, Arun A.
Sandhu, Shahneen
Violet, John
Hofman, Michael S.
[J]. EUROPEAN UROLOGY, 2019, 75 (06) : 927 - 928

← 1 2 3 4 5 →